Streetbeat News

Earnings

IONQ

IonQ Inc's Q2 revenue increased 111% YoY to $5.5 million, beating the consensus estimate of $4.35 million. However, the company reported a quarterly loss of 22 cents per share, missing analyst estimates for a loss of 13 cents per share. IonQ achieved $28 million in new bookings in Q2 and ended the quarter with $509.2 million in cash, equivalents, and investments. The company raised its full-year revenue outlook to a range of $18.9 million to $19.3 million and its full-year 2023 bookings expectations to a range of $49 million to $56 million. Despite these positive results, IonQ shares fell in after-hours trading due to the earnings miss.

Portfolio Pulse from Adam Eckert

August 10, 2023 | 8:26 pm

ACB

Aurora Cannabis reported Q1 sales of $55.91M, surpassing the estimated $46.80M.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:26 pm

SIEN

Sientra has projected its FY23 net sales to be between $98M and $102M, which is lower than the estimated $104.51M.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:26 pm

IONQ

IonQ expects its Q3 revenue to be between $4.8M and $5.2M, compared to the estimated $4.94M.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:26 pm

ZYME

Zymeworks (NYSE:ZYME) reported Q2 losses of $(0.75) per share, missing the analyst consensus estimate of $(0.47) by 59.57%. The company also reported quarterly sales of $7.00 million, missing the analyst consensus estimate of $12.36 million by 43.35%. However, this represents an increase in losses and sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:26 pm

SIEN

Sientra reported Q2 losses of $(0.85) per share, beating the analyst consensus estimate of $(0.86) by 1.16 percent. However, the company's quarterly sales of $23.13 million missed the analyst consensus estimate of $24.75 million by 6.55 percent.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:25 pm

ASXC

Asensus Surgical reported Q2 losses of $(0.09) per share, missing the analyst consensus estimate of $(0.08) by 12.5%. This is a 28.57% decrease over losses from the same period last year. However, the company's quarterly sales of $1.08 million beat the analyst consensus estimate of $1.07 million by 1.03%, marking an 8.75% increase over sales from the same period last year.

Portfolio Pulse from vinayak@benzinga.com

August 10, 2023 | 8:25 pm

IONQ

IonQ has projected its FY23 revenue to be between $18.9M and $19.3M, which is in line with the estimated $19.29M.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:25 pm

CANO

Cano Health reported worse-than-expected Q2 financial results, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:25 pm

VTGN

VistaGen Therapeutics reported Q1 losses of $(0.94) per share, a 68.67% increase from $(3.00) per share YoY. Sales were $117.00K, a 62.27% decrease from $310.10K YoY.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:24 pm